vaccines

Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO).  WHO has released the first-ever report1 looking at the pipeline of vaccines currently in development to fight infections caused by (AMR)  It […]

GSK and Sanofi have reported positive efficacy data from a co-developed vaccine targeting the Omicron variant of Covid-19.   The report makes GSK and Sanofi the first companies to have a vaccine candidate for the Omicron variant which has demonstrated efficacy.  Specifically, the companies’ B.1.351 vaccine candidate demonstrated 64.7% efficacy in symptomatic Covid-19 adults and 72% […]

GSK is to invest £1 billion over the course of 10 years into research on infectious diseases that largely affect low-income countries.   In particular, the pharmaceutical company will aim to develop new vaccines and medicines that prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR) – all […]

News round-up by DDW’s Reece Armstrong for 20-24 June. Covid-19 vaccine development and research, gene therapies for dementia and a ‘game-changing’ treatment for HIV are some of the themes of this week’s news round-up. Moderna to set up mRNA vaccine centre in UK  Pharmaceutical company Moderna is to set-up a manufacturing and research development centre […]

By Greg Kulnis  – Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Companies have needed to rapidly […]

Despite continuous work by the scientific community, malaria remains one of the largest and deadliest diseases on the planet. The disease, which is spread via the bites of female Anopheles mosquitoes, was responsible for 627,000 deaths in 2020, with 95% of those occurring in Africa.    The disease largely affects at-risk groups such as infants, children […]

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new study   Animals with a large difference in lifespan and size end their natural lives […]

Specialist RNA process developer eTheRNA Manufacturing has introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.  This new LNP service uses eTheRNA’s proprietary lipid libraries and formulations to facilitate targeted delivery and tailored biodistribution solutions. Through working with the company’s […]

Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in South Africa), three lineage variants […]

Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  – and indeed remain the ultimate standard for advancing new drugs to markets – gathering observational data from clinical settings […]